StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Reported (IFRS) R&D expense by Quarter

Reported (IFRS) R&D expense ($M) ($M)

QuarterlyAnnual

AstraZeneca Reported (IFRS) R&D expense: -$4,053M in Q2 2026, up 14.2% from a year earlier.

Latest, Q2 2026
-4,053
Period ended Jun 30, 2026
Change on a year earlier
+14.2%
-3,548 in Q2 2025
History
27 quarters
Since Q2 2017
Sources
26
Documents cited below

Where the Q2 2026 figure comes from

“|| R&D expense | | (4,053) | | | 36 | | | 355 | | – | | (3,662) | 6 | 5”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Consolidated Income Statement.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedReported (IFRS) R&D expense ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026-4,053+14.2%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 2026-3,492+10.5%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 2025-3,862-17.4%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 2025-3,663+17.6%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 2025-3,548+18.0%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 2025-3,159+13.5%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 2024-4,677+52.2%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 2024-3,115+20.5%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 2024-3,008+12.8%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 2024-2,783+6.6%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 2023-3,073+17.1%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 2023-2,584+5.1%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 2023-2,667+4.8%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 2023-2,611+22.4%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 2022-2,625+1.6%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 2022-2,458-31.9%Form 6-K FY2022Q3 Earnings Release ↗

Cite this data

StockData. (2026). AstraZeneca Reported (IFRS) R&D expense ($M), quarterly Q2 2017–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/rep-rd-cmp

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.